The activities of 10 combinations of antifungal agents against 25 clinical isolates of Scopulariopsis brevicaulis were tested by the checkerboard technique. An average indifferent effect was detected for all combinations. Synergy was observed for some isolates and combinations, particularly with posaconazole-terbinafine (68% of strains), amphotericin B-caspofungin (60%), and posaconazole-caspofungin (48%).
Antifungal agents. Antifungal agents utilized were amphotericin B (Sigma-Aldrich Química, Madrid, Spain), terbinafine (Novartis Pharma AG, Basel, Switzerland), itraconazole (Janssen Pharmaceutica, Madrid, Spain), voriconazole (Pfizer Ltd., Sandwich, United Kingdom), posaconazole (Schering-Plough, Kenilworth, NJ), and caspofungin (Merck & Co., Inc., Rahway, NJ).
Antifungal susceptibility testing. The individual MICs were determined by following the Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) reference method (26) with the following minor modifications: the medium was RPMI 1640 with L-glutamine (buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid [MOPS] and 10 M NaOH) supplemented with 2% glucose (Oxoid, Madrid, Spain); the inoculum size was 1 ϫ 10 5 to 5 ϫ 10 5 CFU/ml; and the inoculum was prepared by microscopic enumeration with a cellcounting hemocytometer (Neubauer chamber; Merck, S.A., Madrid, Spain). Several reports have demonstrated that these modifications generate reproducible, reliable, and accurate in vitro susceptibility data (9, 11, 14, 17, 31) . For caspofungin, two different visual determinations of the end point were performed: (i) complete inhibition of growth (MIC) and (ii) the lowest drug concentration resulting in aberrant hyphal growth as determined by examination with an inverted microscope, the minimum effective concentration (MEC) (2, 35) .
Interaction of drugs in vitro. Drug interaction was evaluated in a checkerboard microdilution design. Combinations tested were amphotericin B plus itraconazole, amphotericin B plus voriconazole, amphotericin B plus posaconazole, amphotericin B plus caspofungin, itraconazole plus caspofungin, voriconazole plus caspofungin, posaconazole plus caspofungin, itraconazole plus terbinafine, voriconazole plus terbinafine, and posaconazole plus terbinafine. The combined effects were analyzed by the summation of the fractional inhibitory concentration index (FICi) (2, 35) . For combinations including caspofungin, FICi was calculated by taking into account both the MIC and the MEC of the echinocandin. The interactions were defined as synergistic when FICi was Յ0.5, as antagonistic when FICi was Ͼ4, and as indifferent, or no interaction, when FICi was Ͼ0.5 but Յ4. Triplicate testing on three separate days was performed.
A summary of MICs of individual antifungal agents against isolates is given in Table 1 . All organisms were highly resistant in vitro to amphotericin B, azole agents, caspofungin, and terbinafine.
Regarding interactions in vitro, an average indifferent effect was detected for all combinations. Synergy was observed for some isolates with some combinations. Posaconazole plus terbinafine exhibited synergy for 17/25 (68%) strains; this combination showed the highest rate of positive effect in vitro. The average FICi for this combination was 0.64. Voriconazole plus terbinafine and itraconazole plus terbinafine also showed synergy for some strains, with rates of 40% and 28%, respectively. Amphotericin B in combination with azole agents did not exhibit synergy for a significant number of isolates. Combinations including caspofungin were largely indifferent when MICs were used for FICi calculation. Notably, antagonism was absent for all antifungal combinations. Table 2 displays average FICi values and numbers and percentages of strains for which synergy was detected per combination analyzed.
S. brevicaulis seems to be a multiresistant species that can usually cause fatal invasive infections in immunocompromised hosts (27, 36, 38) . Taking into account the resistance of S. brevicaulis, other therapeutic approaches should be considered and combined therapy could be useful, particularly for immunosuppressed patients with disseminated infections (6, 7) .
Until now, the combined activity of antifungal agents against S. brevicaulis had not been evaluated. Here we present the in vitro activities of 10 combinations of antifungal compounds against 25 clinical isolates of S. brevicaulis. An average indifferent effect was observed for all combinations, but synergistic interaction was detected for a significant percentage of strains with some combinations. The rate was particularly high with posaconazole plus terbinafine, where synergy was observed for 68% of strains analyzed. Other combinations, such as amphotericin B plus caspofungin, posaconazole plus caspofungin, and voriconazole plus caspofungin, also showed synergistic effects against a number of organisms.
Data on the clinical efficacy of combination therapy in cases of Scopulariopsis infection are too scarce to draw any firm conclusions. Steinbach et al. (36) reported a case of disseminated infection due to S. brevicaulis in a child with graft-versushost disease after stem cell transplantation who failed lipid amphotericin B therapy as well as combination therapy with voriconazole plus caspofungin. For other Scopulariopsis spp., successful therapy has been reported (3, 19) . Combination therapy could be an alternative for treating deep infections due to Scopulariopsis, but the effect of combinations is not predictable and depends on the strain tested. Therefore, studies of interaction in vitro would be needed before therapeutic recommendations could be made.
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